Tetraploidy in BRCA2 breast tumours

Area of Science:

• Genetics
• Oncology
• Cell Biology

Background:

• Cell division errors, such as tetraploidy and aneuploidy, are common in human carcinomas.
• BRCA2 tumor suppressor is implicated in cell division completion, with delayed cytokinesis observed in BRCA2 mutation carriers.
• Ploidy aberrations in breast tumors from BRCA2 germline mutation carriers warrant investigation.

Purpose of the Study:

• To investigate ploidy aberrations in breast tumors from BRCA2 germline mutation carriers.
• To compare ploidy distribution between BRCA2-mutated and matched sporadic breast cancers.
• To examine the association of ploidy differences with molecular tumor subtypes.

Main Methods:

• Flow cytometry histograms were used to evaluate ploidy aberrations in 236 breast tumor samples.
• Samples were pre-screened for local BRCA mutations.
• Ploidy distribution was compared between 71 BRCA2-mutated and 165 matched sporadic cancers.
• Differences were analyzed concerning molecular tumor subtypes defined by immunohistochemistry.

Main Results:

• Tetraploidy was significantly 3 times more frequent in BRCA2-associated breast cancers compared to sporadic cancers.
• No significant differences in overall ploidy distribution were found between BRCA2 mutation carriers and non-carriers.
• In BRCA2-associated cancers, tetraploidy was predominantly linked to luminal molecular subtypes.
• Tetraploidy was less common in triple-negative BRCA2 breast cancers.

Conclusions:

• The increased frequency of tetraploidy in BRCA2-associated breast cancers may stem from cell division errors, particularly cytokinesis defects.
• Tetraploidy in BRCA2 breast cancers is predominantly associated with luminal phenotypes, suggesting subtype-specific mechanisms.
• These findings highlight a potential role for BRCA2 in maintaining genomic stability in specific breast cancer subtypes.